1. Five drugs, including two from Novartis, win EMA endorsement —What’s next for Amarin’s stock after FDA panel recommendation — Shionogi antibiotic scores FDA ok— See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Earnings call 11/06

Discussion in 'Aerie Pharma' started by anonymous, Nov 7, 2019 at 5:48 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Disaster!
     
  2. anonymous

    anonymous Guest

    Stay POSITIVE!!!!!!!!!!
     
  3. anonymous

    anonymous Guest

    Yeah, because a 22% dump of the stock in one day is so positive.
     
  4. anonymous

    anonymous Guest

    To be expected with an emerging biotech! It will be up 35% in 2020.
     
  5. anonymous

    anonymous Guest

    Actually, its not. When a company slashes guidance every quarter and keeps lowering expected revenue outlook, it means that the people running it are not forecasting properly.

    That's why the stock is down 34% for the year, despite the market being up 18.1% and the biotech sector up 3.7%. The trend in biotech is up, not down.

    This type of devaluation has the company looking for alternative sources of capital.

    None of this is "expected" from a second year commercialization effort unless you are delusional.
     
  6. anonymous

    anonymous Guest

    Fake News from a fired sales rep!! Troll someplace else.
     
  7. anonymous

    anonymous Guest

    Definitely not true..
     
  8. anonymous

    anonymous Guest

    Never underestimate the power of denial
     
  9. anonymous

    anonymous Guest

  10. anonymous

    anonymous Guest

    Let’s talk about #fail/mistakes. We are a start up company. A performance based company. Why would you screw all of the top reps over in the 4th quarter? The ONLY people who bring $$$ into this company? Instead you lower the goals so that the bottom reps who bring no value.... nothing to this company’s bottom line and set most of them up so they move into the top and get huge bonus payouts? Really? Big mistake.
     
  11. anonymous

    anonymous Guest

    Everyone adds to the bottom line. Not just you. Get over yourself
     
  12. anonymous

    anonymous Guest

    That’s laughable! There are some territories that shouldn’t even have reps.... keep drowning.
     
  13. anonymous

    anonymous Guest

    I agree. The docs are being paid to prescribe in some territories.
     
  14. anonymous

    anonymous Guest

    Your compensatory projection of confidence, is a guarantor of its lack.

    And your inability to understand how territories differ due to marketplace conditions only adds to the depths of your misperception.
     
  15. anonymous

    anonymous Guest

    Is English your 1st language? U def speak Fucktardo so im just wondering
     
  16. anonymous

    anonymous Guest


    What this person means is that the people who have had top spots all year actually now have to grow instead of relying on managed care and KOL’s who are being paid to write to do the work.
     
  17. anonymous

    anonymous Guest

    How about alerting C. Davis to the fact that KOLs are being paid to Rx.
    She did nothing about that at Sun, so don’t expect anything different here.
     
  18. anonymous

    anonymous Guest

    They did it at ISTA

    They do it here too
     
  19. anonymous

    anonymous Guest

    The fact that someone with such terrible character and over the top entitlement works here is horrifying. How did they get hired??? Who wants that on their team?
     
  20. anonymous

    anonymous Guest

    So true. Some of these territories have 50trx in a quarter . The reps in these territories are being compensated more than the actual revenue that the territory generates to the company . And now they are to get paid a huge bonus payout for underperformance? Wow. A start up company being run like big pharma. We should all be worried about the stock price. Great job!